BOSCOLO BIELO, LUCA
BOSCOLO BIELO, LUCA
Universita' degli Studi di MILANO
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
2024 L. Cantini, D. Trapani, L. Guidi, L. Boscolo Bielo, R. Scafetta, M. Koziej, L. Vidal, K.S. Saini, G. Curigliano
Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates
2024 S. Natangelo, D. Trapani, C. Koukoutzeli, L. Boscolo Bielo, G. Marvaso, B.A. Jereczek-Fossa, G. Curigliano
Future potential targets of antibody-drug conjugates in breast cancer
2023 C. Corti, L. Boscolo Bielo, A.C. Schianca, B.T. Salimbeni, C. Criscitiello, G. Curigliano
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
2023 C. Valenza, D. Trapani, S. Gandini, C. Sposetti, L. Boscolo Bielo, A. Marra, T. Giarratano, D. Favero, L. Cortesi, L. Moscetti, M. Pistelli, R. Berardi, A. Zambelli, M. Lambertini, L. Del Mastro, V. Guarneri, C. Vernieri, G. Curigliano
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano